Biological Times

Volume No. 5 | Issue No. 7 | Pages 8-9

An Overview: Nutritional Management of Chronic Kidney Disease Patients

Ifza Siddiqui[1*], Daniya Muzammil Khan[1], Amama Sadia[2], Mansoor Ali[3] and Warda Siddiqui[4]

1. Faculty of Human Nutrition and Dietetics, Hamdard University Main Campus, Karachi, Pakistan
2. Faculty of Human Nutrition and Dietetics, Riphah International University, Lahore, Pakistan
3. Herbiverse Organic Healthcare Services, Tehsil Sohawa, District Jhelum
4. Faculty of Pharmacy, Hamdard University Main Campus, Karachi, Pakistan

*Corresponding Author: **ifzasiddiqui30@gmail.com**

ABSTRACT

As chronic kidney disease (CKD) progresses, the specifications and usage of different nutrients change significantly. These changes are supported by multiple nutritional and metabolic irregularities that are identified in the continuum of kidney disease. To provide appropriate care to patients with CKD, it is necessary to have a perception of the applicable nutritional principles: an approach to assess dietary status, establish patient-specific nutrient needs, and prevent or treat possible or ongoing dietary deficiencies and derangements. The keywords utilized were "chronic kidney disease," "administration," and "principles." The incorporation conditions were researched to ensure administration directions for individuals with CKD. The majority of the article focused on managing Kidney Disease Improving Global Outcomes findings, clinical recommendations, the most commonly acknowledged, and guidance for the management of CKD. The research identified that the recommendations highlight the significance of initial recognition and control of CKD and the demand for a strategy that includes numerous interventions in its treatment.

Keywords: Chronic kidney disease, kidney diet, medical nutrition therapy, electrolyte balance

To cite this article: Siddiqui I, DM Khan, A Sadia, M Ali & W Siddiqui. An Overview: Nutritional Management of Chronic Kidney Disease Patients. Biological Times. 2026. July 5(7): 8-9.

Introduction

As chronic kidney disease (CKD) advances, the requirements and consumption of different dietary components change significantly. These changes are accompanied by multiple nutritional and biochemical abnormalities that are used to monitor the progression of kidney disease. To allocate optimal care to patients with CKD, an arrangement of the applicable dietary principles and the processes for assessing nutritional classification, establishing personalized dietary needs, and preventing or managing potential or ongoing nutrient deficiencies and imbalances is essential [1]. Given the diverse structure**.** For patients with CKD, meticulous nutrition plays an essential role in this population [2]. Adequate intake with enough protein and energy may reduce PEW. While nutritional therapy for improving kidney malfunction remains_arguable**,** previous studies have shown that it can help control uremia, electrolyte and acid-base imbalances, water and salt retention, and mineral and bone disorders (MBD) [3]. Chronic inflammation in patients with CKD can cause protein catabolism through raised insulin resistance, and protein catabolism can substantially impair an individual's nutritional status [3,4].

Patients with CKD may experience hyperkalemia, excess phosphate, anorexia, as well as severe muscle and fat loss. Protein-energy wasting (PEW) was first explained in 2007 by the International Society of Renal Nutrition and Metabolism as a condition of nutritional and metabolic derangements distinguished by the loss of structural body protein and energy stores in patients with non-dialysis CKD and KF [5]. The incidence of PEW in patients with early to moderate CKD was stated to be 20% to 25%, increasing as kidney dysfunction develops up to 75% in KF [6]. Malnutrition reduced physical activity, uremia-induced increased breakdown, acidosis, and ongoing inflammation can all lead to PEW [7,8], which is related with increased chance of hospitalization and mortality [9]. Dietary adjustment can reduce the buildup of waste products, which may reduce uremic symptoms and postpone the beginning of maintenance dialysis treatment in patients with non-dialysis CKD. Hence, nutritional management should be carefully planned during all stages of CKD, and all physicians caring for patients with CKD should be informed of the dietary and nutritional condition of these patients [10]. This review is concentrated on several features of nutritional management in patients with CKD.

Definition and Epidemiology:

Chronic kidney disease is a significant global health concern that affects millions of people worldwide [1]. The epidemiology of CKD is multifactorial and influenced by several factors, including age, sex, race/ethnicity, and associated illness. Approximately 15% of adults in the United States are affected by CKD, with prevalence increasing among high-risk populations, with higher rates noticed in the aging population, African Americans, and Hispanics. In Asia, the incidence of CKD is estimated to range from 10% to 15%, with an elevated load of the disease in countries including China and India [1]. Chronic kidney disease (CKD) has appeared as one of the leading causes of death and distress in the 21st century. Due in part to the increase in risk factors, such as obesity and diabetes mellitus, the number of patients influenced by CKD has also been rising, affecting approximately 843.6 million individuals worldwide in 2017 [1]. Even though mortality has reduced in patients with end-stage kidney disease (ESKD) [2]. The overall Burden of Disease (GBD) studies have shown that CKD has appeared as a leading cause of worldwide mortality [3,4].

The prevalence of CKD varies across different populations and is influenced by several factors such as age, sex, race/ethnicity, and multimorbidity [5]. In the United States, the prevalence of end-stage renal disease (ESRD) resulting from CKD is highest among African Americans, followed by Hispanics, Native Americans, and Asians [5]. Similarly, in Asian countries such as Japan and South Korea, the prevalence of ESRD is more prevalent among older adults [6]. Studies in the USA, all executed with the same methodology, discover that the prevalence of the advanced stages G3–4 CKD has remained stable since 2000. The age-standardized incidence of CKD is higher in females (9.5%) than in males (7.3%), possibly because of the high prevalence of pregnancy-related kidney complications (7–9). But CKD-related death rate is higher in males than in females (18.9 compared with 13.6 per 100,000 population), possibly because additional risk factors for premature death are more prevalent in males [7].

Pathophysiology:

Although AKD is a usual sequela of acute conditions throughout hospital admission, often under-recognized, this is complicated because AKD is related to increased morbidity, prolonged unfavorable consequences, and death rate worldwide [8]. However, AKD has not been extensively investigated, and its long-term clinical outcomes remain poorly understood. In a large-scale study involving 62,977 hospitalized adults with preserved baseline kidney function [8]. A large scale found that AKD occurred in 2.2%, while AKI was observed in 7.7%. Among the study population, 906 (1.4%) developed AKD with AKI, whereas 485 patients (0.8%) experienced AKD without AKI. Patients with AKD without AKI had a significantly higher risk of major adverse kidney events (36.21 per 100 person-years; hazard ratio [HR] 2.26, 95% confidence interval [CI] 1.89–2.70), CKD (22.94 per 100 person-years; sub-HR 2.69, 95% CI 2.11–3.43), kidney failure (0.28 per 100 person-years; sub-HR 12.63, 95% CI 1.48–107.64), and all-cause mortality (14.86 per 100 person-years; HR 1.57, 95% CI 1.19–2.07). Older patients and those with multiple comorbidities were more susceptible to AKD [8,9]. The glomerular capillaries are particularly susceptible to injury because glomerular filtration depends on high intra- and trans-glomerular pressure; consequently, a disease process that increases these pressures may adversely affect glomerular function. Glomerular hypertension and hyperfiltration are 2 major mechanisms

implicated in the progression of chronic kidney disease (CKD) [9]. Chronic Kidney disease may develop as a result of cellular injury that damages, including regions of the kidney that were not directly affected by the initial insult or nephrotoxic agent [9]. Compared with its acute counterpart, acute kidney disease (AKI), CKD is generally associated with a more progressive and detrimental disease course [10]. The kidneys receive a greater blood supply than most other well perfused, making them particularly susceptible to exposure to potentially nephrotoxic substances [11].

Laboratory and Diagnostic Abnormalities:

Laboratory abnormalities: The kidneys play a vital role in maintaining homeostasis through their essential function of filtration, reabsorption, and secretion. The kidney plays an important role in the management of extracellular fluid volume, serum osmolality, and electrolyte balance. They are also responsible for the excretion of metabolic waste products and toxins, including urea, creatinine, and uric acid, as well as the production of hormones, such as erythropoietin, 1,25-dihydroxy vitamin D, and renin [16]. Chronic kidney disease (CKD) disrupts the kidneys' homeostatic function, leading to fluid and electrolyte imbalances, endocrine and metabolic disorders, and hematological abnormalities. Therefore, the laboratory irregularities in CKD include impaired glomerular filtration associated with the Renin-Angiotensin System (RAS), which medically manifests as proteinuria [17]. Fluid and electrolyte disturbances in CKD may lead to hyponatremia, high K+, fluid overload, hyperphosphatemia, hyperchloremia, and metabolic acidosis. Endocrine and metabolic complications include hyperuricemia, abnormal lipid metabolism (characterized by hypertriglyceridemia, decreased high-density lipoprotein (HDL) levels), vitamin D deficiency, and elevated parathyroid hormone (PTH) levels. These irregularities commonly contribute to chronic kidney disease-mineral and bone disorder (CKD-MBD), a systemic disorder of mineral and bone metabolism characterized by abnormalities of calcium, phosphorus, PTH, or vitamin D metabolism.

Treatment:

It is remarkable that in CKD patients on protein-controlled diets, it is required to guarantee high energy consumption, an acceptable supply of essential amino acids, and adjustments of metabolic acidosis. These are the circumstances needed to acquire a correct modification to protein constraint and to evade a negative nitrogen balance [18]. To this aim, essential tools for focusing on energy and amino acid sufficiency are illustrated by the protein-free products as well as the combination of essential amino acids and ketoacids [19]. The most recent instructions for controlling CKD are available from the KDIGO framework. These instructions were most recently updated in 2020 [22].

The primary suggestion for controlling chronic kidney disease (CKD), according to Kidney Disease Improving Global Outcomes (KDIGO) guidelines, includes exact and timely analysis and staging of CKD using the Kidney Disease Outcome Quality Initiative (KDOQI) or KDIGO classification criteria. Detecting and controlling causes of CKD development, such as hypertension, glycemic control in diabetes, cholesterol control, tobacco cessation, and weight control. Consistently and regularly assess kidney function, proteinuria, arterial blood pressure, and remaining causes for CKD development. The Use of the renin-angiotensin-aldosterone system (RAAS) blockade is recommended for patients with proteinuria and hypertension, except when contraindicated. In addition, non-steroidal anti-inflammatory drugs should be used with caution in patients with CKD patients and nephrotoxic agents should be avoided whenever possible. Assessment and treatment of CKD-related adverse effects, such as iron deficiency, CKD mineral and bone disorder (CKD - MBD), cardiovascular complications, and communicable diseases. Instructions and guidance for patients with CKD to support self-management practices and compliance with treatment. Refer to a nephrology physician as suitable, according to the patient's CKD stage and advancement risk. These instructions ensure an extensive intervention for directing CKD and can be adopted to enhance treatment outcomes and well-being.

Conclusion:

Chronic kidney disease (CKD) is a developing, irreversible condition that can ultimately lead to ESRD, requiring dialysis or kidney transplantation. Over time, different management recommendations have been advanced to refine clinical care with CKD and decrease the risk of adverse outcomes. The existing management instruction for CKD recommends immediate recognition and treatment to delay or stop the progression of the disease. This includes routine observation of kidney function, hypertension management, and healthy practices, such as a balanced diet, regular physical activity, and tobacco cessation. The clinical recommendation also suggests using pharmacological therapy to control disease-related complications such as iron deficiency, mineral and bone density(CKD-MBD), and cardiovascular disorder. Now, but care distribution still needs to be modified to take full advantage of the advances. Over the past ten years, the emergence of more possibilities to improve the identification and treatment of CKD has been expected. Impending change, proactively rather than reactively, will best serve the extension of diagnostic measures and management options. A key area for investigation is the progress of blood and urine biomarkers, and collaboration with large clinical studies can be used to aid molecular phenotyping. Continuous recognition of patient encounters should inform analysis strategies and modifications to care delivery.

References

[1] MacLaughlin, H. L., Friedman, A. N., & Ikizler, T. A. (2022). Nutrition in Kidney Disease: Core Curriculum 2022. American Journal of Kidney Diseases, 79(3), 437-449.

[2] Kalantar-Zadeh K, Moore L Precision Nutrition and Personalized Diet Plan for Kidney Health and Kidney Disease Management. Journal of Renal Nutrition, 30, 365-367.

[3] Kim, S. M., & Jung, J. Y. (2020). Nutritional management in patients with chronic kidney disease. The Korean Journal of Internal Medicine, 35(6), 1279.

[4] Elendu C, Elendu RC, Enyong JM, Ibhiedu JO, Ishola IV, Egbunu EO, Meribole ES, Lawal SO, Okenwa CJ, Okafor GC, Umeh ED. Comprehensive review of current management guidelines of chronic kidney disease. Medicine. 2023 Jun 9;102(23):e33984.

[5] Kovesdy, C. P. (2022). Epidemiology of chronic kidney disease: An update 2022. Kidney International Supplements, 12(1), 7-11. https://doi.org/10.1016/j.kisu.2021.11.003

[6] Kung, C. W., & Chou, Y. H. (2023). Acute kidney disease: An overview of the epidemiology, pathophysiology, and management. Kidney Research and Clinical Practice, 42(6), 686. https://doi.org/10.23876/j.krcp.23.001.

[7] Borriello, M., Tarabella, G., Liboà, A., Barra, M., Vurro, D., Lombari, P., Coppola, A., Mazzella, E., Perna, A. F., & Ingrosso, D. (2023). Lab on a Chip Device for Diagnostic Evaluation and Management in Chronic Renal Disease: A Change Promoting Approach in the Patients' Follow Up. Biosensors, 13(3), 373.

[8] Pérez-Torres, A., Caverni-Muñoz, A., & González García, E. (2022). Mediterranean Diet and Chronic Kidney Disease (CKD): A Practical Approach. Nutrients, 15(1), 97.

[9] Eckardt, K., Delgado, C., Heerspink, H. J., Pecoits-Filho, R., Ricardo, A. C., Stengel, B., Tonelli, M., Cheung, M., Jadoul, M., Winkelmayer, W. C., & Kramer, H. (2023). Trends and perspectives for improving quality of chronic kidney disease care: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 104(5), 888-903. https://doi.org/10.1016/j.kint.2023.05.013

[10] Carrero, J. J., St-Jules, D. E., Biruete, A., Cuppari, L., Piccoli, G. B., Picard, K., Hansen, N. M., Sabatino, A., Winkelman, D., & Avesani, C. M. (2026). Quality-oriented diet therapy for chronic kidney disease. Nature Reviews Nephrology, 22(4), 252-264.

[11] Tom K, Young VR, Chapman T, et al. Long-term adaptive responses to dietary protein restriction in chronic renal failure. Am J Physiol Endocrinol Metab. 1995;268:E668–677.

[12] Aparicio M, Bellizzi V, Chauveau P, Cupisti A, Ecder T, Fouque D, Garneata L, Lin S, Mitch W, Teplan V, Yu X, Zakar G. Do Ketoanalogues Still Have a Role in Delaying Dialysis Initiation in CKD Predialysis Patients? Semin Dial. 2013;26:714–9

[13] Padial M, Rebollo A, Jiménez-Salcedo T, López V, Avesani CM, Lindholm B, Qureshi AR, Olveira G. A Pilot Clinical Trial of a Nutrition Education Program on Quality of Life in CKD. Clin J Am Soc Nephrol. 2025 Oct 1;20(10):1352-1364. doi: 10.2215/CJN.0000000790. Epub 2025 Aug 19. PMID: 40828609; PMCID: PMC12537290.

[14] Steiger, S. et al. Sex dimorphism in kidney health and disease: mechanistic insights and clinical implications. Kidney Int. 107, 51–67 (2025).

[15] Baylis A, Zhou W, Menkhorst E, Dimitriadis E. Prediction and prevention of late-onset pre-eclampsia: a systematic review. Frontiers in Medicine. 2024 Nov 21;11:1459289.